DP8 Stock Chart & Stats
€2.14
-€0.08(-3.51%)
At close: 4:00 PM EDT
€2.14
-€0.08(-3.51%)
Day’s Range― - ―
52-Week Range€1.81 - €8.45
Previous CloseN/A
Volume0.00
Average Volume (3M)15.00
Market Cap
€30.83M
Enterprise Value€6.82M
Total Cash (Recent Filing)€24.94M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Nov 16, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding15,119,096
10 Day Avg. Volume46
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.80Price Target Upside544.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.92
Revenue Forecast (FY)€237.43K
Bulls Say, Bears Say
Bulls Say
Clinical Biomarker ProgressThe Phase 2a biomarker signal provides evidence that neflamapimod may affect a marker of neuronal degeneration in a rare dementia population. If supported by the trial’s later controlled period, this could strengthen the lead program’s clinical rationale and broader development potential.
Improved Formulation And DosingThe tablet and dosing advances could improve development execution by reducing formulation variability and enabling a regimen designed to maintain therapeutic trough levels. FDA removal of the prior exposure limit also gives the company greater flexibility as it advances clinical testing.
Debt-free Capital StructureA debt-free balance sheet reduces interest and refinancing pressure while preserving flexibility to allocate capital toward clinical development. Positive equity provides a financial base, although the benefit is partly offset by the company’s ongoing losses and need to fund operations.
Bears Say
Minimal Commercial RevenueThe very small revenue base shows that CervoMed has not yet reached meaningful commercial scale, while the large net loss reflects substantial development spending. Until a product generates material revenue, earnings remain highly dependent on clinical progress and future financing.
Persistent Cash BurnSustained operating and free-cash-flow outflows indicate that the business cannot currently fund its activities from internally generated cash. Continued development therefore depends on external financing unless spending moderates or revenues scale, creating ongoing funding and dilution risk.
Clinical Execution RiskFailure to reproduce earlier efficacy results demonstrates that neflamapimod’s clinical benefit is not yet established across study settings. Although the company identified exposure and patient-selection factors, additional trials must validate the revised strategy before commercial potential becomes more credible.
CervoMed News
DP8 FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was €1.81 and its highest was €8.45 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is €30.83M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Nov 16, 2026 which is in 25 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Aug 10, 2026. The company reported -€0.563 earnings per share for the quarter, beating the consensus estimate of -€0.738 by €0.175.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.43.
How many shares outstanding does CervoMed have?
CervoMed has 15,119,096 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -€0.563 in its last earnings report, beating expectations of -€0.738. Following the earnings report the stock price went up 4.464%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in DE:DP8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.80 (544.97% Upside)
€13.80 (544.97% Upside)
Blogger Sentiment
Bullish
DE:DP8 Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.59%
12-Months-Change
Fundamentals
Return on Equity
-156.02%
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
DP8 Stock 12 Month Forecast
Average Price Target
€13.80
▲(544.97% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―